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Abstract: The effect of analogue Pd(II)-, Pt(II)-, and Au(III) compounds featuring 
2-(2’-pyridyl)benzimidazole on the aggregation propensity of amyloid-like peptides derived from 
Aβ and from the C-terminal domain of nucleophosmin 1 was investigated. Kinetic profiles of 
aggregation were evaluated using thioflavin binding assays, whereas the interactions of the 
compounds with the peptides were studied by UV-Vis absorption spectroscopy and electrospray 
ionization mass spectrometry. The results indicate that the compounds modulate the aggregation 
of the investigated peptides using different mechanisms, suggesting that the reactivity of the metal 
center and the physicochemical properties of the metals (rather than those of the ligands and the 
geometry of the metal compounds) play a crucial role in determining the anti-aggregation 
properties. 
Keywords: amyloid aggregation; metallodrugs; gold(III) compounds; platinum(II) compounds; 
palladium(II) compounds; anti-aggregation properties 
 
1. Introduction 
The research field involving the use of metal-based drugs as inhibitors of amyloid fibril 
formation and toxicity, targeting neurodegenerative diseases like Alzheimer’s (AD) and Parkinson’s 
Disease (PD), is experiencing a great flowering [1,2]. In general, transition metal complexes have 
tunable properties, depending on the oxidation and spin states of the metal center as well as the 
coordination geometry. All these features could influence the reactivity of these compounds with 
amyloidogenic species and consequently modulation of their aggregation pathways [3,4]. 
Metal complexes of relatively kinetically inert metal ions (such as Pt(II) square-planar 
complexes) can form stable coordinate bonds with amyloidogenic peptides in their monomeric state 
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[5]. Selective modulation of self-recognition mechanisms was obtained by using Pt compounds 
bearing hydrophobic phenanthroline(phen)-based bidentate ligands and two monodentate ligands 
(e. g. chlorides) [5]. These molecules bind Aβ1–40 via the exchange of the monodentate ligands 
followed by coordination of the Pt(II) center to the imidazole of His residues [6]. The metal 
complexes target the N-terminal domain of Aβ through π-π interactions between the phen ligand 
and the aromatic residues of the peptide (Phe4, Tyr10, and Phe19). (Pt(II)(phen)–Aβ)2+ adducts, formed 
upon the coordination of the metal center to Aβ residues, inhibit peptide aggregation by causing the 
precipitation of amorphous aggregates rather than the formation of amyloid fibrils. The 
(Pt(II)(phen)–Aβ)2+ adducts also limit the neurotoxicity of Aβ and protect against Aβ-induced 
synaptotoxicity in mouse hippocampal tissue [6]. The aromatic interactions cause an acceleration in 
the rate of substitution of ligands of the metal center as demonstrated by results obtained with Aβ1-16, 
a shorter variant of Aβ1–40 [7]. Similar results have been obtained using a water-soluble sulfonated 
analogue, (PtCl2(4,7-diphenyl-(1,10)phenanthroline disulfonate)), providing a mixture of products 
primarily involving the coordination to the sulfur atom of Met35 [8], while the reaction of cisplatin 
does not affect any of the biochemical and cellular effects of Aβ1–40 [6]. 
Direct coordination of the Pt center to amyloid peptides/proteins is not the only strategy that 
has been identified to inhibit the formation of amyloid fibers. It has been shown that metal-driven 
oxidation of crucial residues could be also exploited [4]. Indeed, the oxidation of Met35 affects the 
aggregation of Aβ1–40 [9]: indeed, when Met35 forms the hydrophilic Met sulfoxide, the electronic 
properties of Aβ peptides vary and cause an enhancement of peptide’s polarity, which hampers 
hydrophobic interactions that are crucial for the initiation and progression of Aβ aggregation. Thus, 
it is possible to trigger the oxidation of Met in amyloid peptides utilizing metal compounds that can 
act as reducing agents or that can produce reactive oxygen species (ROS) which can be responsible 
for the oxidation [10]. 
Beyond Pt(II) complexes, other metal complexes have been used as inhibitors of amyloid fiber 
formation. Due to the ligand field similarities between Pd(II), Au(III), and Pt(II) compounds, the 
ability of Pd(II) and Au(III) compound to inhibit the fiber formation has been investigated 
[11–14,15]. Pd(II) compounds can exchange ligands 105 times faster than their Pt(II) analogues [16], 
enhancing their capability to interact with the cellular components such as sulfur-donor 
biomolecules. To overcome this issue, chelating ligands were used to increase the thermodynamic 
stability of these metal compounds [17,18]. Chelating ligands have been also used to increase the 
stability of Au(III) complexes in aqueous solvents [19]. Pd(II) complexes containing chelate ligands 
bind prion protein (PrP) fragments with high affinity and site selectivity. In particular, these 
molecules can bind the peptide 106-126 of the prion protein (PrP106–126) close to the imidazole of a His 
residue that has a crucial role for aggregation [20,21] or close to amide nitrogen atoms of the peptide, 
significantly inhibiting the peptide aggregation propensity [15]. Gold-sulfur complexes bind 
PrP106–126 [13] and the human islet amyloid peptide [12] via metal coordination and hydrophobic 
interactions. 
Here we report on the ability of Pd(II), Pt(II), and Au(III) complexes, bearing 
2-(2′-pyridyl)benzimidazole as a ligand (Figure 1), to modulate amyloid-like aggregation of two 
model amyloid peptides. The complexes bearing the pyridylbenzimidazole skeleton with sulfonate 
ligands form different types of DNA-complex adducts [22]. They exhibit high cytotoxicity against 
non-cancerous cells such as HEK293 human embryonic kidney cells [22–24]. They are able to bind 
the model proteins hen egg white lysozyme and bovine pancreatic ribonuclease, as already reported 
for similar complexes [25,26], both non-covalently and via coordination to side chains of protein 
residues [27]. 
Peptide sequences chosen as a model of amyloids are reported in Table 1. They are: i) the 
fragment corresponding to the 2nd helix (residues 264–277) of the C-terminal domain of 
nucleophosmin 1 (NPM1264–277), which is able to form amyloid-like assemblies and fibrils toxic to 
neuroblastoma cells [28–33] and ii) the fragment spanning residues 21–40 of the beta-amyloid 
peptide Aβ (Aβ21–40) [34]. 
Pharmaceutics 2019, 12, 154 3 of 16 
 
Chosen protein fragments demonstrated directly involved in the aggregation mechanism of the 
related proteins, NPM1c+ [35] and Aβ1–42 [36]. 
 
Figure 1. Chemical structures of square-planar complexes investigated in this study. 
Table 1. Peptide sequences analyzed in this study. 
Peptide Sequence pI Net Charge at pH7 
NPM1264–277 VEAKFINYVKNCFR 10.15 1.9 
Aβ21–40 AEDVGSNKGAIIGLMVGGVV 3.93 −1 
2. Materials and Methods 
2.1. Peptide and Metal Compound Synthesis 
Peptide sequences analyzed in this study were synthesized as previously reported [37], in 
acetylated and amidated version and are reported in Table 1. Reagents for chemical synthesis were 
obtained from Iris Biotech (Marktredwitz, Germany) and solvents were purchased from Romil 
(Dublin, Ireland). Peptides were treated with HFIP (at 50% (v/v) in water), purified through 
RP-HPLC and then identified through LC-MS system LCQ DECA XP Ion Trap mass spectrometer 
from ThermoFisher (Waltham, MA, USA). Purified peptides were lyophilized and stored at −20 °C 
until use. A small aliquot of Aβ21–40 was oxidized at 1mg/mL in phosphate buffer (100 mM, pH = 7.2, 
H2O2 0.1% (v/v)), under stirring for 20 h and then further purified [38]. 
The metal compounds (Figure 1) were synthetized as previously described [22,39]. 
2.2. Interaction of the Metal Compounds with Amyloid Peptides 
2.2.1. UV-Vis absorption spectroscopy 
The reactivity of 1–3 towards amyloid peptides was spectrophotometrically investigated at  
25 °C in 10 mM borate buffer at pH = 9.0 for NPM1264–277 and 10 mM sodium phosphate buffer at pH 
= 7.4 for Aβ21–40. The final concentration of DMSO (Merck KGaA, Darmstadt, Germany) in these 
solutions was < 0.5%. The electronic absorption titration was carried out at a fixed concentration of 
the compounds (40 µM), gradually increasing the concentration of peptides by adding 1.0 µL of 2 
mM stock solutions in water, kept at 0 °C. Following this addition, the solutions were stirred for 5 
min and the spectrum was recorded. These conditions ensured a prevalent monomeric state of 
added peptides allowing to evaluate each addition in terms of equivalents to each metal complex. 
Spectra are reported in the ranges 240–500 and 280–500 nm for Aβ21–40 and NPM1264–277, respectively. 
In control experiments, the stability of compounds under the investigated experimental 
conditions were tested using UV-Vis absorption spectroscopy (see Figure S1 and Supporting info for 
further details). UV-Vis absorption spectra of 1–3 as a function of time were recorded over 24 h on a 
Varian Cary 5000 UV-Vis-NIR spectrophotometer at 25 °C in 10 mM sodium phosphate buffer at pH 
7.4 and 10 mM borate buffer pH at 9.0. Other experimental settings were wavelength range: 240–700 
nm, scan-time: 600 nm/min, band width: 2.0 nm, data pitch: 1.0 nm. The three compounds have been 
dissolved in 100% DMSO and then added to the selected buffers at a final concentration of 5 × 10−5 M. 
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The final concentration of DMSO is < 0.5%. The stability of complexes was also evaluated in 10 mM 
ammonium acetate buffer at pH 6.8 that was employed for mass samples (Figure S1), see below. 
Since NPM1264–277, has an intrinsic absorption band at 275 nm due to the presence of a Tyr residue, an 
additional control experiment was carried out to assess that observed signal variations are due to an 
effective interaction of the metal compounds with the peptide (Figure S2) [22,39]. 
2.2.2. ESI-MS Analyses of the Adducts among Metal Complexes and Amyloid Peptides 
Solutions of NPM1264–277 and Aβ21–40 at a concentration of 100 µM and 50 µM respectively were 
incubated in 15 mM ammonium acetate at pH 6.8 with a 1:10 peptide:complex molar ratio, at 25 °C. 
Incubation times were fixed to 0, 3, and 17 h and analyzed by using a Q-ToF Premier (Waters, 
Milford, MA, USA) by direct injection at 10 µL/min flow rate. The source parameters were: 3.7 kV for 
capillary voltage and 42 kV for cone voltage. The acquisition range was set from 600 to 2500 m/z for 
NPM1264–277 and from 700 to 2500 m/z for Aβ21–40. Raw data were elaborated by using MassLynx 4.1 
software (Waters, Milford, MA, USA). Peptides in the absence of the metal complexes were analyzed 
as controls (see Figures S3 and S4 in Supporting info). 
2.3. Fluorescence Assays 
To study the aggregation propensity of the peptides in the absence and in the presence of the 
metal complexes, thioflavin (ThT) fluorescence time-course experiments were carried out at 25 °C 
using a Jasco FP 8300 spectrofluorometer (JASCO, Tokyo, Japan). λexc: was set to 440 nm, while λem 
was set to 483 nm. ThT concentration was 50 µM, peptide concentration was 100 µM. The solution 
was maintained under magnetic stirring in a 10 mm path-length quartz cuvette. Experimental 
conditions: 0.1% DMSO, 10 mM borate buffer (Merck KGaA, Darmstadt, Germany) at pH = 9.0 for 
NPM1264–277 and 0.1% DMSO, 10 mM sodium phosphate buffer for Aβ21–40. Reported fluorescence 
values are the mean of two independent experiments. 
3. Results and Discussion 
3.1. The Aggregation Propensity of Amyloidogenic Peptides is Affected by the Presence of 1, 2, and 3 
The ability of 1–3 to affect the aggregation process of NPM1264–277 and Aβ21–40 was monitored 
through time-course ThT fluorescence emission. For both peptides, the no-zero starting values of 
ThT fluorescence is due to a fast aggregation during sample preparation, as already observed [5,28]. 
The presence of the metal complex causes a decrease of ThT signal when compared to the signal of 
the peptides alone, suggesting an inhibitory effect on amyloid self-aggregation. Different starting 
intensities suggest that quenching/direct binding mechanisms between metal complexes and ThT 
can occur. In detail, when NPM1264–277 is stirred with 1, after 50 min, a slow reduction of the 
fluorescence signal is observed. At the end of the experiment, the ThT fluorescence value presents an 
intensity comparable with the starting value of the peptide alone (Figure 2A). A more significant 
decrease in the emission intensity was observed when the ThT fluorescence of the peptide was 
recorded in the presence of 2. In this case, a lower signal with respect to t = 0 is attained after 5 
minutes, while after 230 min the fluorescence intensity is very low. The ThT fluorescence signal of 
the peptide is also significantly affected by the presence of 3. After a steady emission of 35 min, a 
significant reduction of the emission, at values comparable to those shown in the presence of 2, is 
observed. 
Similar results were obtained with Aβ21–40 peptide (Figure 2B), indeed both 1 and 2 provided a 
slow signal decrease, delayed with respect to NPM1264–277, while the presence of 3 seems to have a 
faster effect on the aggregation process. 
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Figure 2. Time-course of ThT fluorescence emission intensity of NPM1264–277 (panel A) and Aβ21–40 
(panel B) in the presence of 1–3, upon incubation at 1:1 peptide to metal compound molar ratio. The 
peptides alone are reported as blue squares. Results are representative of two independent 
experiments. 
3.2. 1. and 2 are Able to Disaggregate Amyloid Assemblies 
The ability of 1 and 2 to disaggregate soluble amyloid aggregates were then evaluated by 
monitoring the ThT signals versus time upon the addition of the metal complexes to NPM1264–277 and 
Aβ21–40 aggregates (Figure 3). As already reported [5], the two peptides have rather different 
aggregation times, since they differ both in amino acidic composition and length. Thus, 1 and 2 were 
added to the aggregates at different times, as indicated in Figure 3 (after 15 min for NPM1264–277 and 
after 90 min for Aβ21–40). 
For NPM1264–277, a fast decrease of ThT fluorescence intensity is observed upon the addition of 
both 1 and 2 (Figure 3A). For Aβ21–40 (Figure 3B), a fast decrease of ThT fluorescence intensity is 
monitored upon the addition of 1, while a slower decrease of fluorescence signal was observed in the 
presence of 2. 
Altogether the results of ThT experiments suggest that the three metal complexes could be able 
to module the aggregation process and that 1 and 2 could also act as disaggregating agents. The 
results obtained on these last experiments also suggest different kinetics of the recognition processes 
of the oligomeric form of Aβ21–40 by 1 and 2. 
 
Figure 3. Time-course of ThT fluorescence emission intensity of NPM1264–277 (panel A) and Aβ21–40 
(panel B) upon addition of 1 (red circle) and 2 (green triangle). The addition is indicated by an arrow. 
Results are representative of two independent experiments. 
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3.3. The Ligand Fields of 1 and 2 are Tuned by the Presence of Amyloidogenic Peptides. 
To understand at the molecular level how the presence of the three compounds can alter the 
aggregation (and in the case of 1 and 2 the disaggregation) process of the investigated 
amyloidogenic peptides, spectroscopic and spectrometric studies were carried out. First, the effects 
of the presence of NPM1264–277 and Aβ21–40 on the spectroscopic properties of 1–3 were investigated. In 
particular, the changes of the intensity and/or of the position of Ligand to Metal or Metal to Ligand 
Charge Transfer (LMCT or MLCT) bands in the UV-Vis absorption spectra [22,39], upon the addition 
of peptide to a solution of the metal compounds at a fixed concentration, were monitored. The 
addition of both amyloid sequences to 1 (Figure 4A) causes slightly shifts of λmax that is 
hypsochromic for NPM1264–277 (at 335 → 333 nm) and bathochromic for Aβ21–40, (290 → 330 nm). These 
features together with the changes in the absorption of the bands suggest a possible modification in 
the ligand field of Pt, which could be associated with the presence of potential Pt ligands in the 
sequence of the peptides (the side chains of residues C, M, E, D, N, K, and R). Amyloid peptides 
affect the absorption spectra also in the case of the Pd compound (Figure 4B). In particular, spectra of 
2 recorded in presence of Aβ21–40 clearly present a progression in a hyperfine resolution of the initial 
band centered at 332 nm. The same experiments carried out for 3 (Figure 4C) do not show significant 
variations of signals. 
 
Figure 4. Absorption spectra of 1 (panel A), 2 (panel B), and 3 (panel C) upon the addition of 
NPM1264–277 (top) and Aβ21–40 (bottom) at different equivalents. (0 eq fuchsia, 0.5 eq black, 1.0 eq 
orange, 1.5 eq blue, 2.0 eq violet, 2.5 eq yellow, 3.0 eq light blue, 3.5 eq green, 4.0 eq grey) Vertical 
arrows indicate changes in intensity, horizontal arrows indicate shifts of λmax. 
3.4. 1. and 2 Form Adducts with NPM1264–277 
More detailed information on the interaction between the peptides and the metal complexes 
were obtained by electrospray ionization mass spectrometry (ESI-MS) (Waters, Milford, MA, USA) 
experiments. ESI-MS analyses of NPM1264–277 and Aβ21–40 in the presence of the metal complexes were 
carried out in a time-dependent way: spectra have been acquired after 0, 3 and 17 h of incubation of 
each peptide with 1–3. 
ESI-MS spectra of NPM1264–277 suggest that the solution of the peptide has a heterogeneous 
composition, due to the presence of a reactive cysteine. Indeed, in addition to the expected species 
with an MW of 1771.20 Da, a dimeric form of NPM1264–277 stabilized by a disulfide bridge (3540.63 
Da) is also present, as well as a species showing a molecular weight of 1874.09 Da (Figure S3A). In 
addition, up to three oxidized species of the NPM1264–277 monomer are present. Under reducing 
conditions, the monomeric form of NPM1264–277 is the only detected species (Figure S3B). 
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ESI-MS spectra of the peptide in the presence of the three metal complexes indicate that 1 and 2 
form adducts with NPM1264–277, whereas 3 does not seem to interact with the peptide. 
ESI-MS spectra of NPM1264–277 in the presence of 1 and 2, just upon the addition of the metal 
compound and after 17 h of incubation are reported in Figure 5. Immediately after the addition of 1, 
ESI-MS spectrum of NPM1264–277 (Figure 5A, upper panel) indicates two predominant species with 
molecular weights of 2278.81 and 4561.57 Da, corresponding to NPM1264–277 monomer and dimer 
bound to one and two fragments of the Pt(II) compounds, respectively. The fragments of the Pt(II) 
adducts correspond to species in which 1 has lost Cl ligands (Table 2). This result is expected, based 
on the observed reactivity of the compound with proteins [22,27]. The amount of dimeric form 
bound to two Pt containing fragments increases over time (Figure 5A, lower panel). The spectra also 
that the NPM1264–277 monomer can bind two Pt containing fragments of 1 at the same time, as 
confirmed by the presence of a species at MW = 2789.96 Da. The presence of NPM1264–277 dimer 
bound to a higher number of Pt-containing fragments (molecular weights 5143.11 Da and 5108.63 
Da, respectively) is also detectable. 
Considering the preference of Pt compounds for specific amino acid residues [40,41], the 
sequence of the peptide and the finding that the Pt fragment binds both monomeric and dimeric 
forms of NPM1264–277, it can be surmised that the most probable Pt binding sites are the side chains of 
lysine residues in positions 4 and 10 and of Glu in position 2. These residues were already found as 
ligands of Pt complexes [40,42,43]. 
Following the incubation of NPM1264–277 with 2, the main species obtained just after the addition 
of 2 is the adduct of NPM1264–277 with one Pd-containing fragment constituted by a molecule of 2 
missing Cl ligands (molecular weight = 2294.11 Da) (Figure 5B, upper panel). This species decreases 
over time (Figure 5B, lower panel). Additionally, the presence of species with molecular weights of 
2189.17 and 2611.21 Da suggests that NPM1264–277 monomer binds one or two molecules of the Pd(II) 
compounds that have lost all Cl ligands NPM1264–277 monomer and dimer also show the ability to 
bind naked Pd(II) ions, indeed, peaks at 3749.08 Da and 1976.95 Da are assigned to NPM1264–277 
dimeric and monomeric adducts with two and one metal ions, respectively. All these findings 
suggest that the state of thiol, free or covalently modified, together with the nature of the metal, 
highly influences the capability to bind the peptide of the investigated compounds. The metal 
complex fragments that are found bound to the peptide agree with those obtained upon reaction of 
the compound with proteins and suggest the possibility that a bidentate mode of binding could 
occur [22,27]. The ESI-MS data collected on the adducts formed in the reaction of NPM1264–277 with 1 
and 2 are also in agreement with previous observations indicating that the investigated Pd 
compound has higher reactivity with proteins than the analogous Pt compound [22,27]. 
Altogether ESI-MS spectra unambiguously demonstrate that 1 and 2 react with the NPM1264–277 
peptide forming stable adducts with a similar fragment (the molecule that has lost the Cl ligands), 
although the Pd compound seems to be able to degrade upon reaction with the peptide. These 
findings suggest that the mechanism of action of the two metal compounds in the aggregation of 
NPM1264–277 could be based on a direct interaction of 1 and 2 with monomeric and/or with low 
molecular weight oligomers of the peptide. Indeed, the finding that the compounds are also able to 
disaggregate the preformed fibrillar assembly suggests that the binding of the compounds to a 
specific site drives the oligomer to monomer equilibrium towards the monomeric species. 
It is also interesting to note that both Pt(II) and Pd(II) compounds affect the oxidation of the Cys 
residue in NPM1264–277. Indeed, in the presence of both complexes, the amount of monomeric and the 
Cys-adduct monomeric species decreases over time, whereas the signals associated with the dimer 
increase (Figures 5A and 5B). 
To evaluate if the oxidation state of NPM1264–277 could have a role in the aggregation process of 
NPM1264–277 in presence of the two compounds, the effect of the Pd(II) compound has been evaluated 
in the presence of DTT as reducing agent. Data, reported in Figure S5, indicate a delay in the 
decrease of fluorescence signal suggesting a role of the oxidation state of NPM1264–277 during its 
self-recognition mechanism. 
Pharmaceutics 2019, 12, 154 8 of 16 
 
3.5. 3 Does not Form Adducts with NPM1264–277, but it Significantly Affects the Number of Oxidized Forms of 
NPM1264-277 
The spectra of NPM1264–277 in the presence of 3 show specific features that are different from 
those observed in the spectra of the peptide collected in the presence of 1 and 2. No traces of adducts 
of 3 with NPM1264–277 can be detected even at longer incubation times. Nevertheless, in presence of 
the Au(III) compound, the intensities of the signals related to NPM1264–277 dimer decrease over time, 
leading to an increase of monomer and of its different oxidized forms (Figure 5C). This finding is in 
line with data indicating that the gold(III) compound reduces upon interaction with proteins [39,44] 
and is in line with what observed when other gold(III) compounds react with proteins and peptides 
[26]. The observed behavior of 3 can be explained on the basis of the reduction of Au(III) to Au(I) 
with thiols/thioethers and with the subsequent dismutation of Au(I) to Au(III) and Au(0). These 
processes can be accompanied by the formation of RSO3H species starting from RSH and RSSR, as 
suggested by some of us [44] and other authors [45]. 
These results indicate that the observed effects in NPM1264–277 aggregation by 3 are not due to a 
direct interaction between the metal complex and the peptide but through an indirect process that 
could involve a redox process. 
 
Figure 5. ESI-MS spectra of NPM1264–277 incubated with: A) 1, at t = 0 (upper panel) and t = 17 h (lower 
panel), B) 2, at t = 0 (upper panel) and t = 17 h (lower panel), C) 3, at t = 0 (upper panel) and t = 17 h 
(lower panel). In panel A, the m/z range between 1500 and 1900 is 10 times magnified. 
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Table 2. Results of the ESI-MS analysis of the adducts formed upon reaction of NPM1264–277 with 1–3. 
The experimental m/z values, the ion charge status, the experimental (Exp) and theoretical (Theor) 
monoisotopic mass values, the corresponding ion species and times of incubation are reported. 
Complex 
Signal 
(m/z) 
Charged 
Species 
Exp MW  
(Da) 
Theor 
MW (Da) Species 
Time 
(h) 
1 
1772.02 
886.50 
A (+1) 
A (+2) 
1770.99 ± 
0.02 1770.91 
Monomer 
(NPM1264–277(M)) 0,3,17 
1875.03 
938.00 
625.68 
B (+1) 
B (+2) 
B (+3) 
1874.02 ± 
0.02 
1873.91 Monomer Adduct  
(NPM1264–277(Madd)) 
0,3,17 
1771.02 
1181.33 
885.99 
709.00 
C (+2) 
C (+3) 
C (+4) 
C (+5) 
3540.22 ± 
0.43 3539.82 
Dimer  
(NPM1264–277(D)) 0,3,17 
1140.539 
760.360 
D (+2) 
D (+3) 
2278.81 ± 
0.52 2281.45 
NPM1264–277(M) + 
(1)−2HCl 0,3,17 
1396.095 
931.070 
E (+2) 
E (+3) 
2789.960 ± 
0.31 2791.9 
NPM1264–277(M) + 
2(1)−4HCl 
0,3,17 
3,17 
1404.60 
936.73 
F (+2) 
F (+3) 
2806.96 ± 
0.30 
2807.9 NPM1264–277(M) + 
2(1)−4HCl + 1Ox† 
0,3,17 
3,17 
1413.099 
942.72 
G (+2) 
G (+3) 
2824.98 ± 
0.60 
2823.9 NPM1264–277(M) + 
2(1)−4HCl + 2Ox 0,3,17 
1521.75 
1141.06 
H (+2) 
H (+4) 
4561.57 ± 
1.00 
4560.9 NPM1264–277(D) 
+2(1)−4HCl 0,3,17 
1704.337 
1278.03 
I (+3) 
I (+4) 
5108.63 ± 
0.50 5107.8 
NPM1264-277(D) + 
3(1)−5HCl 
0,3 
0,3,17 
1715.37 J (+3) 5143.11* 5144.25 
NPM1264–277(D) + 
3(1)−4HCl 0,3 
2 
1772.146 
886.560 
A (+1) 
A (+2) 
1771.12 ± 
0.02 1770.91 
Monomer  
(NPM1264–277(M)) 0,3,17 
1875.100 
938.060 
625.720 
B (+1) 
B (+2) 
B (+3) 
1874.11 ± 
0.02 
1873.91 Monomer Adduct  
(NPM1264–277(Madd)) 
0,3,17 
1771.14 
1181.07 
886.06 
709.25 
C (+2) 
C (+3) 
C (+4) 
C (+5) 
3540.47 ± 
0.44 3539.82 
Dimer  
(NPM1264–277(D)) 0,3,17 
1148.026 
765.69 
D (+2) 
D (+3) 
2294.11 ± 
0.09 2295.96 
NPM1264–277(Madd) + 
1(2)−2HCl 0,3,17 
989.476 E (+2) 1976.952* 1976.32 NPM1264–277(Madd) + 1Pd  0,3,17 
1095.587 F (+2) 2189.17* 2192.79 
NPM1264–277(M) + 
1(2)−2HCl 0,3,17 
1306.606 G (+2) 2611.21* 2614.58 
NPM1264–277(M) + 
2(2)-4HCl  0,3,17 
1201.721 H (+3) 
3602.19 ± 
0.04 3604.00 NPM1264–277(D) + 4Ox 3,17 
1250.694 I (+3) 3749.082* 3748.84 NPM1264–277(D) + 2Pd  0,3,17 
3 
1772.03 
886.51 
A (+1) 
A (+2) 
1771.02 ± 
0.01 1770.91 
Monomer  
(NPM1264–277(M)) 0,3,17 
938.00 
625.68 
B (+2) 
B (+3) 
1874.98 ± 
0.05 
1873.91 Monomer Adduct  
(NPM1264–277(Madd)) 
0,3,17 
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1771.52 
1181.01 
886.01 
C (+2) 
C (+3) 
C (+4) 
3540.35 ± 
0.48 
3539.82 Dimer (NPM1264–277(D)) 0,3,17 
893.51 D (+2) 1785.02* 1786.91 NPM1264–277(M) +1Ox 0,3,17 
902.50 E (+2) 1803.00* 1802.91 NPM1264–277(M) +2Ox 0,3,17 
910.51 F (+2) 1819.02* 1818.91 NPM1264–277(M) +3Ox 0,3,17 
*error not available. †Ox refers to the presence of oxygen atoms on cysteine residues. 
3.6. Interactions of the Metal Complexes with Aβ21–40 
The ESI-MS spectra of Aβ21–40 in absence of metal complexes highlight a weakness of the peptide 
bonds under the experimental conditions used for this analysis. During spectra acquisition using 
standard source settings, the peptide undergoes a fragmentation process, as evidenced by the 
presence in the spectra of several b-series signals (See Figure S4). 
Just after the addition of 1 to Aβ21–40 (Figure 6A and Table 3), the peptide binds a Pt-containing 
fragment that has lost a Cl ligand, as indicated by the presence of the peak at 2471.54 Da. Over time, 
the peptide binds a Pt-containing fragment that has lost an additional Cl ligand (MW = 2435.59 Da). 
When Aβ21–40 is incubated with 2 (Figure 6B), it immediately binds one molecule of the Pd(II) 
compound that has released two Cl ligands, as inferred from the species of 2346.03 Da molecular 
weight. Moreover, the presence of an adduct of 2029.00 ± 0.02 Da suggests that Aβ21-40 binds also a 
naked Pd(II) ion, as observed when the compound reacts with NPM1264–277. The adducts formed by 
Aβ21–40 with 1 and 2 are also present in the signals belonging to b-series. This finding suggests that 
the Aβ21–40 N-terminal tail is directly involved in metal compound recognition. 
As observed in the reaction with NPM1264–277, 3 does not form adducts with Aβ21–40 (Figure 6C). 
However, the presence of the metal complex affects the oxidation state of the peptide. In particular, 
it promotes the oxidation of Met35, as demonstrated by a slight increasing of Aβ21–40 oxidized form 
over time (1941.68 Da). 
These findings suggest that both the direct binding of metal complexes to the peptide and the 
oxidation of Met35 can be used as valuable strategies to inhibit the Aβ21–40 aggregation. These results 
are in line with previous data indicating that Met35 has a role in the aggregation process of Aβ1–40 
[9,46]. To further corroborate this hypothesis, time-course ThT emission experiments on the oxidized 
Aβ21–40 were carried out (Figure S6). Data indicate that oxidized Aβ21–40 is unable to aggregate as its 
parent peptide Aβ1–40 [46]. 
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Figure 6. ESI-MS spectra of Aβ21–40 incubated with: A) 1, at t = 0 (upper panel) and t = 17 h 
(lower panel), B) 2, at t = 0 (upper panel) and t = 17 h (lower panel), C) 3, at t = 0 (upper panel) 
and t = 17 h (lower panel). In all panels, signals belonging to the fragmentation b series of 
Aβ21–40 are indicated. b series fragmentation signals deriving from Aβ21–40 complexed with metal 
compounds are indicated with an asterisk. 
Table 3. Results of the ESI-MS analysis of the adducts formed by the reaction of Aβ21–40 with 1, 2 and 
3. The experimental m/z values, the ion charge status, the experimental (Exp) and theoretical (Theor) 
monoisotopic mass values, the corresponding ion species and times of incubation are reported. 
Complex Signal (m/z) 
Charged 
species 
Exp MW 
(Da) 
Theor MW 
(Da) Species 
Time 
(h) 
1 
1927.48 
964.27 
A (+1) 
A (+2) 
1926.50 ± 
0.02 
1926.00 Aβ21–40 0,3,17 
1943.49 
972.12 
B (+1) 
B (+2) 
1942.35 ± 
0.13 
1942.00 Aβ21–40+ 1Ox† 0,3,17 
1218.583 
813.429 
C (+2) 
C (+3) 
2435.59 ± 
0.56 
2436.45 Aβ21–40 + 
1(1)-2HCl 
0,3,17 
1236.599 
824.641 
D (+2) 
D (+3) 
2471.54 ± 
0.36 
2472.9 Aβ21–40 + 
1(1)-1HCl  
0,3,17 
0,3 
2 
1927.09 
964.03 
A (+1) 
A (+2) 
1926.07 ± 
0.02 1926.00 Aβ21–40 0,3,17 
1943.07 
971.48 
B (+1) 
B (+2) 
1941.50 ± 
0.56 1942.00 Aβ21–40 + 1Ox 0,3,17 
2030.029 
1015.500 
C (+1) 
C (+2) 
2029.00 ± 
0.02 2028.42 Aβ21–40 + 1 Pd  0,3,17 
1174.035 
783.022 
D (+2) 
D (+3) 
2346.03 ± 
0.02 2347.79 
Aβ21–40 + 
1(2)-2HCl 0,3,17 
3 
1927.31 
963.60 
A (+1) 
A (+2) 
1925.74 ± 
0.56 1926.00 Aβ21–40 0,3,17 
1943.28 
971.56 
B (+1) 
B (+2) 
1941.68 ± 
0.58 1942.00 Aβ21–40 +1Ox 0,3,17 
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† Ox refers to the presence of an oxygen atom on the methionine residue. 
4. Conclusions 
Pd(II)-, Pt(II)-, and Au(IIII)- complexes have been investigated for their ability to negatively 
modulate the aggregation of amyloid and amyloid-like peptides. However, a comparative study of 
the influence of the metal center on this inhibitory effect of the compound is missing. Here, the role 
of the metal center in the aggregation inhibitory activity of metal complexes bearing a benzimidazole 
ligand was investigated using analogues Au(III), Pt(II), and Pd(II) compounds. To the best of our 
knowledge this is the first paper reporting the effect of the metal center of analogous metal 
compounds on the aggregation of amyloid-like peptides. Two different sequences were 
investigated: the fragment corresponding to the 2nd helix of the C-terminal domain of 
nucleophosmin 1 (NPM1264–277), encompassing residues 264–277, which is able to form amyloid-like 
assemblies and fibrils toxic to neuroblastoma cells, and the fragment spanning residues 21–40 of the 
Aβ amyloid peptide (Aβ21–40). The investigated compounds significantly modulate the overall 
aggregation process of the peptides in vitro, strongly suggesting an inhibitory action, even though 
only future morphological data deriving from electronic microscopy investigations can definitively 
assess the inhibition of the formation of amyloid fibers. In this respect, it should be noted that 
cytotoxicity experiments carried out using the investigated complexes have been reported to have 
CC50 values in the nanomolar range [22], while employed amyloid peptides, Aβ21–40 and NPM1264–277, 
showed cytotoxicity at high micromolar concentrations. These findings hamper the possibility to 
observe inhibition of toxicity of amyloid aggregates in presence of metal complexes. Thus, only 
future studies carried on different full-length amyloid proteins could confirm the anti-aggregation 
properties of this class of complexes and its potential therapeutic application in neurodegenerative 
diseases. On the other hand, our data provide interesting information on the peptide/metal 
compound recognition process. In detail the Pt and the Pd compounds interact with the peptides 
forming adducts with Pt- and Pd-containing fragments directly coordinated to residue side chains, 
while the Au compound does not directly interact with the peptides, although it significantly alters 
their redox state (as depicted in Figure 7). These data indicate that the compounds can use different 
mechanisms of action in the aggregation process of the peptides. This suggests that the modulation 
of aggregation process of amyloid peptide by metal compounds depends on a lot of factors that 
include, but are not limited to, oxidation state of metal, redox potential, stability, strength of 
metal-bond, total charge of the complex. 
 
Figure 7. Schematic representation of the different mechanisms of action of compounds 1, 2, and 3 in 
the modulation of the aggregation of amyloid peptides analyzed in this study. Pt and Pd compounds 
interact with the peptides forming adducts with Pt- and Pd-containing fragments directly 
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coordinated to residue side chains, while the Au compound does not directly interact with the 
peptides, but it alters the oxidation state of specific residues. In the figure, residues are indicated as 
cyan spheres. They are colored in yellow when present an altered oxidation state. 
Supplementary Materials: The following are available online at www.mdpi.com/1424-8247/12/4/154/s1, Figure 
S1: UV-Vis absorption spectra of 1 (panel A), 2 (panel B), and 3 (panel C) over 24 h under the following 
experimental conditions: 10 mM ammonium acetate buffer pH 6.8, 10 mM sodium phosphate buffer pH 7.4 and 
10 mM borate buffer pH 9.0. Spectra have been acquired at a compound concentration of 5*10−5 M. Final 
concentration of DMSO is 0.5%; Figure S2: Absorption spectra of NPM1264-277 at increasing concetrations 
(indicated by arrow) that correspond to those added during the titration in presence of 1, 2 and 3, reported in 
Figure 5 upper panel. (0 µM fuchsia, 20 µM black, 40 µM orange, 60 µM blue, 80 µM violet, 100 µM yellow, 120 
µM light blue, 140 µM green, 160 µM grey); Figure S3: ESI-MS spectra of NPM1264-277 alone in the absence (panel 
A) and in the presence (panel B) of DTT. Component A: monomer (MM = 1771.17+0.16 Da); component B: 
adduct (MM = 1873.98+0.05 Da); component C: dimer (MM = 3540.01+0.01 Da); Figure S4: ESI-MS spectrum of 
Aβ21-40 peptide alone. Component A: Aβ21-40 (MM = 1926.24+0.05 Da); B:Met oxidized Aβ21-40: (MM = 1941.67+0.60 
Da). Aβ21-40 fragments belonging to b-series and spontaneously generated in source are also present; Figure S5. 
Time course of ThT fluorescence emission intensity of NPM1264-277 in presence of 2 and DTT (10 mM) as reducing 
agent; Figure S6: Time course of ThT fluorescence emission intensity of Aβ21-40 in reduced and oxidized forms. 
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